US2006183163A1PendingUtilityA1

Methods and compositions for screening for modulators of IgE synthesis, secretion and switch rearrangement

Assignee: RIGEL PHARMACEUTICALS INCPriority: May 12, 1998Filed: Mar 9, 2006Published: Aug 17, 2006
Est. expiryMay 12, 2018(expired)· nominal 20-yr term from priority
C12Q 1/6897G01N 2500/10G01N 33/5023C07K 14/70578C07K 2319/00C12N 15/63C12N 15/1079G01N 33/5008C12N 2510/00G01N 33/5047
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to methods and compositions useful in screening for modulators of IgE synthesis, secretion and switch rearrangement.

Claims

exact text as granted — not AI-modified
1 - 28 . (canceled)  
     
     
         29 . A cultured mammalian cell comprising: 
 a nuclear genome comprising a recombinant nucleic acid comprising: 
 a) an IL-4 inducible fragment of an IgG epsilon promoter; and  
 b) a polynucleotide encoding a reporter protein;  
   wherein said IL-4 inducible fragment of said IgG epsilon promoter and said polynucleotide encoding said reporter protein are operably linked such that expression of said reporter protein is IL-4 inducible.    
     
     
         30 . The cultured mammalian cell of  claim 29 , wherein said cultured mammalian cell is an IgM +  B cell.  
     
     
         31 . The cultured mammalian cell of  claim 29 , wherein said reporter protein is an optically detectable protein, a death protein, or a survival protein.  
     
     
         32 . The cultured mammalian cell of  claim 29 , wherein said reporter protein is an optically detectable protein.  
     
     
         33 . The cultured mammalian cell of  claim 29 , wherein said reporter protein is a fusion protein.  
     
     
         34 . The cultured mammalian cell of  claim 33 , wherein said fusion protein comprises two reporter domains.  
     
     
         35 . The cultured mammalian cell of  claim 33 , wherein said fusion protein comprises an IgE heavy chain domain and reporter domain.  
     
     
         36 . The cultured mammalian cell of  claim 33 , wherein said IgG epsilon promoter is endogenous to said nuclear genome.  
     
     
         37 . The cultured mammalian cell of  claim 33 , wherein said IgG epsilon promoter is exogenous to said nuclear genome.  
     
     
         38 . The cultured mammalian cell of  claim 29 , further comprising nucleic acid encoding a test peptide.  
     
     
         39 . The cultured mammalian cell of  claim 29 , wherein said peptide comprises a random sequence of amino acids.  
     
     
         40 . A method of using the cultured mammalian cell of  claim 29 , comprising: 
 contacting said cultured mammalian cell with a test agent; and    detecting an effect of said test agent on IL-4 inducible expression of said reporter protein.    
     
     
         41 . The method of  claim 40 , wherein said agent is an organic molecule having a molecular weight of less than 2500 Da.  
     
     
         42 . The method of  claim 40 , wherein said contacting comprises introducing said test agent into said cell.  
     
     
         43 . The method of  claim 40 , wherein said agent is a polypeptide or polynucleotide page 19, lines 23-25  
     
     
         44 . The method of  claim 40 , wherein said nucleic acid encodes a random peptide.  
     
     
         45 . A method of making the cultured mammalian cell of  claim 29 , comprising: 
 introducing into a cell a vector comprising a recombinant nucleic acid comprising: 
 a) an IL-4 inducible fragment of an IgG epsilon promoter; and  
 b) a polynucleotide encoding a reporter protein; and  
   culturing said cell under conditions for selection for cells in which said recombinant nucleic acid has integrated into said genome.    
     
     
         46 . The method of  claim 45 , further comprising selecting a cell that does not detectably produce said reporter protein in the absence of IL-4.  
     
     
         47 . The method of  claim 45 , wherein said vector is a retroviral vector.

Join the waitlist — get patent alerts

Track US2006183163A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.